Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants

Обзор

This trial is open label, comparative, randomized, phase I/II study, experimental, randomized, open-label, three arm parallel group study. The primary objective for phase I is to evaluate the safety of the DTwP-Hepatitis B-Hib-IPV (Bio Farma) vaccine within 7 days after each dose. The primary objective for phase II is to evaluate protectivity of DTwP-Hepatitis B-Hib-IPV (Bio Farma) vaccine.

Подробное описание

This trial is open label, comparative, randomized, phase I/II study. For phase I, approximately 75 subjects will be recruited and will seamlessly continue to phase II recruiting 390 subject, in total 465 subjects.

In this study, DTwP-Hepatitis B-Hib-IPV (Bio Farma) vaccine will be compared to an active control (Registered DTwP-Hepatitis B-Hib Vaccine and Registered Inactivated Polio Vaccine). There are 2 formulas of DTwP-Hepatitis B-Hib-IPV Vaccine which will be used in the study. The regimen of the vaccine is 0,5 ml injected three-dose regimen with 28 days interval between doses. On the other hand, the control group will receive 0,5 ml of Registered DTwP-Hepatitis B-Hib vaccine and 0,5 ml Inactivated Bio Farma vaccine injected in three-dose regimen with 28 days interval between doses.

The safety and immunogenicity result of the Phase I study will determine the continuation of the next phase clinical trial. Clinical trial of phase II can be conducted after safety observation within 28 days after the third dose in phase I. Three hundred and ninety (390) healthy subjects aged 6-11 weeks of age will be recruited in Phase II trial.

Вмешательства

• Биопрепарат DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A
  0,5 ml DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A injected three-dose regimen with 28 days interval between doses. Vaccine is injected intramuscularly in left anterolateral thigh.
• Биопрепарат DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B
  0,5 ml injected of DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B three-dose regimen with 28 days interval between doses. Injected intramuscularly in left anterolateral thigh.
• Биопрепарат Registered DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac)®
  The control group will receive 0,5 ml of Registered DTwP-Hepatitis B-Hib vaccine and 0,5 ml IPV (Sinovac)® injected in three-dose regimen with 28 days interval between doses. Registered DTwP-Hepatitis B-Hib Vaccine are injected intramuscularly into the left antero-lateral thigh region. IPV (Sinovac)® vaccine are injected intramuscularly into the right mid-lateral thigh region

Первичные конечные точки

• Phase I: Safety of the DTwP-Hepatitis B-Hib-IPV (Bio Farma) vaccine within 7 days after each dose [Срок оценки: From enrollment to 7 days after first dose]
• Phase II: Immunogenicity of DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine [Срок оценки: From enrollment up to 28 days after third dose]

Вторичные конечные точки (12)

• Phase I: Safety of the vaccine within 28 days after last dose [Срок оценки: From enrollment to 28 days after each dose]
• Phase I: Safety of the vaccine within 6 months after last dose [Срок оценки: From enrollment up to 6 months after the last dose]
• Phase I: Comparison of safety within 28 days after each dose between vaccines and active control [Срок оценки: From enrollment to 28 days after each dose]
• Phase I: Comparison of safety until 6 months after last dose between vaccines and active control [Срок оценки: From enrollment to 6 months after last dose]
• Phase I: Routine laboratory evaluation that probably related to the vaccination [Срок оценки: From enrollment to 7 days after first dose]
• Phase I: Serological response to diphteria toxoid and tetanus toxoid [Срок оценки: 28 days after the last dose immunization]
• Phase I: Serological response to the pertussis component (agglutinins) [Срок оценки: 28 days after the last dose immunization]
• Phase I: Geometric mean of anti-HbsAg [Срок оценки: 28 days after the last dose immunization]
• Phase I: Serological response to Hib/PRP [Срок оценки: 28 days after the last dose immunization]
• Phase I: Serological response to polio type 1, 2, and 3 (humoral immunity) [Срок оценки: 28 days after the last dose immunization]
• Phase II: Serological response to diphtheria toxoid, tetanus toxoid [Срок оценки: 28 days after the last dose immunization]
• Phase II: Serological response to the pertussis component (agglutinins) [Срок оценки: 28 days after the last dose immunization]

Критерии участия

Критерии включения

• Infant 6-11 weeks of age.
• Infant born after 37-42 weeks of pregnancy.
• Infant weighing more than 2.5 kg at birth.
• Father or mother, or legally acceptable representative properly informed about the study and signed the informed consent form.
• Parents will commit themselves to comply with the indications of the investigators and with the schedule of the trial.

Критерии исключения

• Child concomitantly enrolled or scheduled to be enrolled in another trial.
• Evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature ≥37.5°C on Day 0).
• Known history of allergy to any component of the vaccines.
• History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection.
• Known history of congenital or acquired immunodeficiency (including HIV infection).
• Child who has received in the previous 4 weeks of a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long term corticotherapy (> 2 weeks).
• Other vaccination within the 7 days prior to inclusion with the exception of BCG and poliomyelitis.
• Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
• Infant with a known history of diphtheria, tetanus, pertussis, Hib, hepatitis B infection.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Профилактика

Центры проведения

Индонезия · 3 центра

• Garuda Primary Health Centre — Bandung
• Ibrahim Adjie Priamry Health Centre — Bandung
• Puter Primary Health Centre — Bandung

Идентификаторы

NCT: NCT06690515 · Hexa 010224

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗